All Cancers - One Solution

SMART-Phage™ for Truly Tumor-Specific Antibody Discovery

All cancers share one feature:

Tn/STn antigens, abundant in tumors - absent in healthy​ cells

Healthy tissue

Tumor tissue

Combotopes' proprietary SMART-Phage™ Antibody Discovery Platform

Tumor specificity

High affinity

Flexibility

  • Novel and revisited cancer targets

  • ADC, BsAb, BiTE, RIT, CART

  • Untouched IP space

We deliver:

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

We offer an attractive win-win partnership business model

  • Upfront, and milestone payments tied to development and regulatory achievements

  • Royalties on product sales

Crystal structure revealing how Combotope antibodies specifically binds cancer-specific Tn-glycoprotein epitopes

Leadership

  • Dr. Klas Ola Blixt

    CO-FOUNDER, INVENTOR, & CEO

    Ola invented the SMART-Phage technology and is an expert in aberrant glycosylation and development of cancer-specific antibodies. With 20+ years in chemical biology and antibodies, he has an H-index of 50, multiple patents, and 15+ years of management experience.

  • Dr. Søren Nyboe Jakobsen

    CO-FOUNDER, CxO

    Søren is an inventor of key patents in molecular display and immune cell detection. He founded Tetramer Shop (acquired by 10x Genomics) and has led innovation at firms like Novo Nordisk, Nuevolution, and Immudex, with strong biotech startup leadership experience.

Common QAs'

Combotope Therapeutics ApS

Diplomvej 381

DK-2800 Kongens Lyngby

Denmark

Contact:

olablixt@combotope.com

Company registration (CVR) no. 44308266

Privacy policy